Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 30:12:1177271917699850.
doi: 10.1177/1177271917699850. eCollection 2017.

Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue

Affiliations

Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue

Jessica Kristof et al. Biomark Insights. .

Abstract

In preclinical studies, heregulin (HRG) expression was shown to be the most relevant predictive biomarker for response to patritumab, a fully human anti-epidermal growth factor receptor 3 monoclonal antibody. In support of a phase 2 study of erlotinib ± patritumab in non-small cell lung cancer (NSCLC), a reverse-transcription quantitative polymerase chain reaction (RT-qPCR) assay for relative quantification of HRG expression from formalin-fixed paraffin-embedded (FFPE) NSCLC tissue samples was developed and validated and described herein. Test specimens included matched FFPE normal lung and NSCLC and frozen NSCLC tissue, and HRG-positive and HRG-negative cell lines. Formalin-fixed paraffin-embedded tissue was examined for functional performance. Heregulin distribution was also analyzed across 200 NSCLC commercial samples. Applied Biosystems TaqMan Gene Expression Assays were run on the Bio-Rad CFX96 real-time PCR platform. Heregulin RT-qPCR assay specificity, PCR efficiency, PCR linearity, and reproducibility were demonstrated. The final assay parameters included the Qiagen FFPE RNA Extraction Kit for RNA extraction from FFPE NSCLC tissue, 50 ng of RNA input, and 3 reference (housekeeping) genes (HMBS, IPO8, and EIF2B1), which had expression levels similar to HRG expression levels and were stable among FFPE NSCLC samples. Using the validated assay, unimodal HRG distribution was confirmed across 185 evaluable FFPE NSCLC commercial samples. Feasibility of an RT-qPCR assay for the quantification of HRG expression in FFPE NSCLC specimens was demonstrated.

Keywords: Real-time reverse-transcription polymerase chain reaction (RT-qPCR); heregulin; non/small cell lung cancer; validation.

PubMed Disclaimer

Conflict of interest statement

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JK and KS are former employees of MolecularMD. XJ, RAB, and DF are former employees of Daiichi Sankyo Pharma Development. WF is an employee of Daiichi Sankyo Pharma Development. KN is an employee of Daiichi Sankyo Co., Ltd. MS was an employee of U3 Pharma GmbH. CS is an employee of MolecularMD.

Figures

Figure 1.
Figure 1.
PCR efficiency and linearity for HRG and 3 housekeeping genes: (A) HRGa,b (B) HMBSb, (C) EIF2B1b, and (D) IPO8b. Ct values as a function of input template. Ct indicates cycle threshold. aThe HRG figure represents a 7-point curve analysis due to no amplification seen in lowest point of 0.01 ng RNA. bEach point represents the mean Ct across 6 runs.
Figure 2.
Figure 2.
Unimodal HRG distribution in NSCLC commercial samples using the validated RT-qPCR assay. Ct indicates cycle threshold; HRG, heregulin. *One sample with ΔCt = −7.2 excluded from the analysis.

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed
    1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-small cell lung cancer. Version 4. http://www.nccn.org. Published 2016. Accessed September 1, 2016.
    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–135. - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, et al. ; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. - PubMed

LinkOut - more resources